Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 10Terminated 3Active not recruiting 2Recruiting 1

Sponsor Class

NIH 3OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

pembrolizumab 185Carboplatin 133Paclitaxel 102Cisplatin 102Gemcitabine 86Pemetrexed 80durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 42Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Diphenhydramine × Clear all
NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡